<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209946</url>
  </required_header>
  <id_info>
    <org_study_id>CaLI</org_study_id>
    <nct_id>NCT04209946</nct_id>
  </id_info>
  <brief_title>Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants</brief_title>
  <acronym>CaLI</acronym>
  <official_title>A Multicenter, Randomized Trial of Preterm Infants Receiving Caffeine and Less Invasive Surfactant Administration Compared to Caffeine and Early Continuous Positive Airway Pressure (CaLI Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sharp Mary Birch Hospital for Women &amp; Newborns</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine whether prophylactic administration of surfactant
      by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical
      ventilation in the first 72 hours of life when compared to early Continuous Positive Airway
      Pressure (CPAP) alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After 5 minutes of life, consented infants that are assessed by a provider as clinically
      stable (i.e. HR&gt; 100 bpm) and spontaneously breathing on CPAP will be randomized by computer
      generated randomization cards placed in opaque envelopes.

      For infants not consented prior to birth, after 5 minutes of life and before 2 hours of life,
      postnatal consent may be obtained for any eligible infant admitted to the NICU and must be
      randomized and receive treatment prior to their two hours of age. Randomization will be
      stratified by gestational age (24-26+6 weeks and 27-29+6 weeks) and labeled as such on each
      envelope. Multiples will be randomized to the same treatment group for ease of consent and
      family considerations.

      Infants randomized to LISA will receive surfactant (Curosurf 2.5 mL/kg, based on estimated
      fetal weight) given in the first 2 hours of life using a conventional or video laryngoscope
      and a small flexible 16 gauge angiocatheter.

      All sites have agreed on using senior level physicians or practitioners that have prior
      experience with the LISA method. An orogastric tube will be placed into the stomach prior to
      laryngoscopy and the contents aspirated after the procedure to document any esophageal
      surfactant administration.

      Infants randomized to early CPAP will be managed according to unit practice for preterm
      infants on CPAP.

      As an unblinded trial it is critical that both groups are standardized to avoid bias towards
      one arm for intubation/treatment failure. Therefore, strict delivery room/NICU criteria will
      be used.

      In the Delivery Room, criteria for intubation will be as specified in the Neonatal
      Resuscitation Program guidelines (7th Ed) and will include:

        1. Chest compressions

        2. Ineffective respiration

        3. Prolonged positive pressure ventilation (PPV)

        4. Prolonged hypoxia

      In the Neonatal Intensive Care Unit (NICU), randomized infants in both groups will only be
      intubated if they meet strict failure criteria :

        1. FiO2&gt; 0.40 required to maintain oxygen saturation &gt;90% for 2 hours after randomization

        2. pH of 7.15 or less OR a partial pCO2 &gt;65 mmHg on any (2) blood gas (arterial/capillary/
           or venous) at least 2 hours after randomization in the first 72 hours of life.

      Infants intubated prior to randomization will be excluded.

      For pragmatic purposes sites will be able to use their standard approach for non-invasive
      ventilation (NCPAP at SMB and NIMV at LLU).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of subjects requiring endotracheal intubation between the two groups (LISA vs CPAP) in the first 72 hours of life</measure>
    <time_frame>Within 72 hours of life</time_frame>
    <description>Required intubation or meeting respiratory failure criteria of having a pCO2 greater than 65 mm Hg or an FiO2 greater than 0.4 for more than 2 hours in the first 72 hours of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation and/or CPAP</measure>
    <time_frame>Through study completion at discharge, up to 6 months of corrected gestational age</time_frame>
    <description>Number of days on mechanical ventilation and/or CPAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen at 36 weeks corrected age</measure>
    <time_frame>Up to 40 weeks of corrected gestational age</time_frame>
    <description>Requiring oxygen therapy greater than 0.21 at 36 weeks corrected age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Grade III and IV intraventricular hemorrhage</measure>
    <time_frame>Through study completion at discharge, up to 6 months of corrected gestational age</time_frame>
    <description>Intraventricular hemorrhage (grades 3-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment outcome at 24 months of corrected gestational age</measure>
    <time_frame>Up to 2 years of corrected gestational age</time_frame>
    <description>Neurodevelopmental assessments using the Bayley Scales of Infant Development 4th ed. will be done at 2 years of corrected corrected age (22-26 months) for subjects who were randomized at birth to receive surfactant by the LISA method versus CPAP alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for repeat surfactant dosing</measure>
    <time_frame>Up to 40 weeks of corrected gestational age</time_frame>
    <description>Requiring more than one dose of surfactant</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laryngoscopy attempt with the LISA procedure</measure>
    <time_frame>Number of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational age</time_frame>
    <description>Total number of laryngoscopy attempts to administer surfactant via the LISA procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Laryngoscopy attempt with endotracheal intubation</measure>
    <time_frame>Number of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational age</time_frame>
    <description>Total number of laryngoscopy attempts to administer surfactant via endotracheal intubation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Premature Lungs</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Surfactant Deficiency Syndrome Neonatal</condition>
  <arm_group>
    <arm_group_label>Less Invasive Surfactant Administration (LISA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants that are spontaneously breathing with a normal heart rate will be randomized to receive prophylactic surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) by the LISA procedure in the first 2 hours of life, using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter. Any repeat dosing for surfactant will be based on clinical indication at the physician discretion by the conventional endotracheal approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Positive Airway Pressure (CPAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants that are spontaneously breathing with a normal heart rate will be randomized to early Continuous Positive Airway Pressure (CPAP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Less Invasive Surfactant Administration LISA</intervention_name>
    <description>Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.</description>
    <arm_group_label>Less Invasive Surfactant Administration (LISA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure CPAP</intervention_name>
    <description>Infant will remain on CPAP Therapy during spontaneous respirations</description>
    <arm_group_label>Continuous Positive Airway Pressure (CPAP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infants born at 24 to 29+6 weeks gestation

          -  Informed consent obtained (antenatal/postnatal)

          -  Infant is spontaneously breathing and maintaining normal heart rate (HR&gt;100 Bpm)

        Exclusion Criteria:

          -  Declined consent

          -  Infants with known congenital anomalies

          -  Requiring intubation prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>29 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anup Katheria</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anup Katheria</last_name>
    <phone>858-939-4170</phone>
    <email>anup.katheria@sharp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Ines</last_name>
    <phone>858-939-4136</phone>
    <email>felix.ines@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Hopper, MD</last_name>
      <email>AHopper@llu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anamika Banerji, MD</last_name>
      <email>ABanerji@llu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women &amp; Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anup Katheria, MD</last_name>
      <phone>858-939-4170</phone>
      <email>anup.katheria@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Felix Ines, RCP-RRT</last_name>
      <phone>858-939-4136</phone>
      <email>felix.ines@sharp.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shandee Hutson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M, Groneck P, Weller U, Möller J, Härtel C, Haller S, Roth B, Herting E; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011 Nov 5;378(9803):1627-34. doi: 10.1016/S0140-6736(11)60986-0. Epub 2011 Sep 29.</citation>
    <PMID>21963186</PMID>
  </reference>
  <reference>
    <citation>Kribs A, Härtel C, Kattner E, Vochem M, Küster H, Möller J, Müller D, Segerer H, Wieg C, Gebauer C, Nikischin W, Wense Av, Herting E, Roth B, Göpel W. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr. 2010 Jan-Feb;222(1):13-7. doi: 10.1055/s-0029-1241867. Epub 2010 Jan 18.</citation>
    <PMID>20084586</PMID>
  </reference>
  <reference>
    <citation>Isayama T, Iwami H, McDonald S, Beyene J. Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2016 Aug 9;316(6):611-24. doi: 10.1001/jama.2016.10708. Review. Erratum in: JAMA. 2016 Sep 13;316(10):1116.</citation>
    <PMID>27532916</PMID>
  </reference>
  <reference>
    <citation>Bhayat S, Kaur A, Premadeva I, Reynolds P, Gowda H. Survey of less Invasive Surfactant Administration in England, slow adoption and variable practice. Acta Paediatr. 2020 Mar;109(3):505-510. doi: 10.1111/apa.14995. Epub 2019 Sep 16.</citation>
    <PMID>31471992</PMID>
  </reference>
  <reference>
    <citation>SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID 3rd, Buchter S, Sánchez PJ, Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010 May 27;362(21):1970-9. doi: 10.1056/NEJMoa0911783. Epub 2010 May 16. Erratum in: N Engl J Med. 2010 Jun 10;362(23):2235.</citation>
    <PMID>20472939</PMID>
  </reference>
  <reference>
    <citation>Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GH, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology. 2017;111(2):107-125. doi: 10.1159/000448985. Epub 2016 Sep 21.</citation>
    <PMID>27649091</PMID>
  </reference>
  <reference>
    <citation>Katheria AC, Leone TA. Changes in hemodynamics after rescue surfactant administration. J Perinatol. 2013 Jul;33(7):525-8. doi: 10.1038/jp.2012.166. Epub 2013 Jan 17.</citation>
    <PMID>23328925</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>Anup Katheria, M.D.</investigator_full_name>
    <investigator_title>Director of Neonatal Research Institute</investigator_title>
  </responsible_party>
  <keyword>Premature Infants</keyword>
  <keyword>Respiratory Distress Syndrome</keyword>
  <keyword>Less Invasive Surfactant administration</keyword>
  <keyword>Continuous Positive Airway Pressure (CPAP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data, particularly data that underlie the results reported in this article after deidentification will be available with other researchers, including data dictionaries for meta-analysis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 6 months and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Data and publication are available at http://clinicaltrials.gov</ipd_access_criteria>
    <ipd_url>http://clinicaltrials.gov</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

